Anti-cytokine Therapeutics: History and Update
Overview
Affiliations
Anti-cytokine therapy has promoted a revolution in the treatment of several inflammatory disorders during the past 10 years. Despite their medical and commercial success, they exhibit several drawbacks: difficulties of production, excessive costs, and a few side-effects. A promising alternative to the passive infusion of monoclonal antibodies or soluble cytokine receptors is the use of the active anti-cytokine immune therapy (ACIT). Surprisingly, clinical studies suggested the interest of this approach during the late 1980's, even before the advent of anti-cytokine passive immunotherapy. In this review, we first explain the involvement of several cytokines in many common diseases involving cytokine overproduction, and identify key targets for anti-cytokine treatments. We then present an update on current advances in preclinical and clinical development of passive anti-cytokine therapeutic approaches. We further discuss progresses in the promising field of active anti-cytokine immunotherapy. Cytokine receptors biologics and small molecules developed using structure/function information, which also constitute important options for treating the cytokine-mediated diseases, are not discussed in this review.
Pang L, Liu C, Gong G, Quan Z Acta Pharm Sin B. 2020; 10(4):628-645.
PMID: 32322467 PMC: 7161710. DOI: 10.1016/j.apsb.2019.09.002.
Modification of the RANKL-RANK-binding site for the immunotherapeutic treatment of osteoporosis.
Ko Y, Lee G, Kim B, Park M, Jang Y, Lim W Osteoporos Int. 2019; 31(5):983-993.
PMID: 31863125 DOI: 10.1007/s00198-019-05200-6.
The Prospects of an Active Vaccine Against Asthma Targeting IL-5.
Bachmann M, El-Turabi A, Fettelschoss-Gabriel A, Vogel M Front Microbiol. 2018; 9:2522.
PMID: 30405579 PMC: 6207595. DOI: 10.3389/fmicb.2018.02522.
Desallais L, Bouchez C, Mouhsine H, Moreau G, Ratsimandresy R, Montes M Sci Rep. 2016; 6:19549.
PMID: 26782790 PMC: 4726013. DOI: 10.1038/srep19549.
Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization.
Brune K, Leneghan D, Brian I, Ishizuka A, Bachmann M, Draper S Sci Rep. 2016; 6:19234.
PMID: 26781591 PMC: 4725971. DOI: 10.1038/srep19234.